{"entity":{"id":"oncoresponse","kind":"company","name":"OncoResponse","aka":["OncoResponse, Inc."],"tldr":"OncoResponse is a Seattle biotech that mines the antibodies of patients who responded exceptionally well to immunotherapy; OR502 blocks LILRB2 to re-educate the suppressive myeloid cells in tumours.","summary":"OncoResponse discovers antibodies from elite responders to cancer immunotherapy, working with MD Anderson Cancer Center. OR502 is a humanised antibody against LILRB2 (ILT4), an inhibitory receptor on macrophages and dendritic cells; blocking it shifts myeloid cells towards an anti-tumour state. OR502 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours. Its earlier antibody OR2805 targets tumour-associated macrophages.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.oncoresponse.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["or502"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seattle, Washington","country":"US","companyType":"biotech","website":"https://www.oncoresponse.com/","investors":[],"funding":[]},"route":"/companies/oncoresponse/","neighbours":{"drug":[{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/"}]}}